Patient Groups Recommend Overhaul For Failing EU Compassionate Use Programs
Executive Summary
An alliance of patient organizations for rare diseases says most EU member states are not doing enough to help patients with life-threatening diseases get timely access to innovative drugs on compassionate grounds. A time difference of more than three years may exist between patients benefiting from a compassionate use treatment, depending on where they live.
You may also be interested in...
French Introduce Time Limit For Drug Approval Applications After Compassionate-Use Award
Companies wanting to make their unapproved products available to patients under the “temporary use authorization” are facing some changes to the way the rules are implemented.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.